Targeting the epigenome for the treatment and prevention of lung cancer.

abstract：:Successful allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation require development of a degree of immune tolerance against allogeneic antigens. T lymphocytes play a critical role in allograft rejection, graft failure, and graft-versus-host disease (GVHD). T-cell tolerance occurs b...

journal_title：Seminars in oncology

authors： Alpdogan O,van den Brink MR

更新日期：2012-12-01 00:00:00

abstract：:Carcinoma of the bladder is the most prevalent cancer in Egypt and in most African countries. At the National Cancer Institute (NCI), Cairo, it constitutes 30.3% of all cancers. The median age at diagnosis is 46 years, with a male preponderance of 5:1. Whether in Egypt or other African countries such as Sudan, Kenya, ...

journal_title：Seminars in oncology

authors： el-Mawla NG,el-Bolkainy MN,Khaled HM

更新日期：2001-04-01 00:00:00

abstract：:Metastatic cancers during pregnancy have historically been associated with dismal outcomes, with greater rates of tumor progression in part because of diminished treatment alternatives. Immunotherapy with T-cell checkpoint inhibitors has significantly impacted the survival of several metastatic tumors. However, given ...

journal_title：Seminars in oncology

authors： Burotto M,Gormaz JG,Samtani S,Valls N,Silva R,Rojas C,Portiño S,de la Jara C

更新日期：2018-06-01 00:00:00

abstract：:Colorectal cancer (CRC) is a common malignancy in the elderly. Randomized trials have demonstrated that adjuvant and palliative chemotherapy for CRC improves survival and quality of life. Unfortunately, there is a lack of evidence-based data about elderly patients to guide decisions regarding therapy. Clinical trials ...

journal_title：Seminars in oncology

authors： Raftery L,Sanoff HK,Goldberg R

更新日期：2008-12-01 00:00:00

abstract：:Non-Hodgkin's lymphoma (NHL) is composed of a group of lymphoid malignancies that has been increasing in incidence at an annual rate of 4% to 7% over the last 20 years in both the United States and Europe. The reasons for this rise in incidence in NHL are not yet defined but most likely involve environmental exposures...

journal_title：Seminars in oncology

authors： Czuczman MS,Fallon A,Mohr A,Stewart C,Bernstein ZP,McCarthy P,Skipper M,Brown K,Miller K,Wentling D,Klippenstein D,Loud P,Rock MK,Benyunes M,Grillo-López AJ,Bernstein SH

更新日期：2002-02-01 00:00:00

abstract：:The potential benefits of docetaxel (Taxotere; Aventis, Antony, France) to patients with previously-treated non-small cell lung cancer have been evaluated in two prospective randomized phase III trials. In one study, patients with stage IIIB/IV non-small cell lung cancer who had failed previous cisplatin-based chemoth...

journal_title：Seminars in oncology

authors： Shepherd FA,Fossella FV,Lynch T,Armand JP,Rigas JR,Kris MG

更新日期：2001-02-01 00:00:00

abstract：:Because studies of breast cancer patients and their relatives provide statistical evidence for involvement of autosomal dominant genes, the identification of specific genetic effects has long been the focus of efforts to identify women at exceedingly high risk. BRCA1, a gene that confers greatly increased susceptibili...

journal_title：Seminars in oncology

authors： Cannon-Albright LA,Skolnick MH

更新日期：1996-02-01 00:00:00

abstract：:In a phase II Eastern Cooperative Oncology Group trial, single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was administered to 26 patients with advanced urothelial cancer who had not received prior systemic chemotherapy. Paclitaxel was given at a dose of 250 mg/m2 by 24-hour continuous infusi...

journal_title：Seminars in oncology

authors： Roth BJ

更新日期：1995-06-01 00:00:00

abstract：:Thrombocytopenia is a significant problem for patients receiving prolonged or aggressive chemotherapy for malignancy. For carboplatin, it is the predominant dose-limiting toxicity and it is cumulative in nature. A number of agents have been evaluated for efficacy in reducing the problem of thrombocytopenia. Some have ...

journal_title：Seminars in oncology

authors： Budd GT,Ganapathi R,Wood L,Snyder J,McLain D,Bukowski RM

更新日期：1999-04-01 00:00:00

abstract：:Hypoxic areas are a characteristic property of solid tumors. Hypoxia results from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature; (2) an increase in diffusion distances; ...

journal_title：Seminars in oncology

authors： Vaupel P,Kelleher DK,Höckel M

更新日期：2001-04-01 00:00:00

abstract：:We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall su...

journal_title：Seminars in oncology

authors： Rajan AM,Rajkumar SV

更新日期：2016-12-01 00:00:00

abstract：:The epidemiologic studies relevant to the hypothesis that exposure to tamoxifen is associated with risk of cancer of the endometrium and perhaps other organs are described, summarized, and evaluated. One large body of data comes from the randomized trials of tamoxifen as a therapeutic agent against established breast ...

journal_title：Seminars in oncology

authors： MacMahon B

更新日期：1997-02-01 00:00:00

abstract：:Over the past 5 years there has been a renewed interest in the use of monoclonal antibodies and immunoconjugates in the treatment of nonhematologic malignancies. This enthusiasm has stemmed from advances in recombinant technology allowing for the production of chimeric and humanized antibodies, from Food and Drug Admi...

journal_title：Seminars in oncology

authors： Murray JL

更新日期：2000-12-01 00:00:00

abstract：:Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor family, which produces factors that are considered to be important mediators of cell growth. Overexpression of HER2, which occurs in approximately 25% to 30% of human breast cancers, has fostered considerable interest i...

journal_title：Seminars in oncology

authors： Ewer MS,Gibbs HR,Swafford J,Benjamin RS

更新日期：1999-08-01 00:00:00

abstract：:The Wayne State University Waldenstrom's Macroglobulinemia xenograft model in mice with severe combined immune deficiency (WSU-WM-SCID) is the only preclinical animal model available for this disease. It is based on a permanent, EBV- IgMlambda cell line (WSU-WM) established from a patient with a 10-year history of Wal...

journal_title：Seminars in oncology

authors： Al-Katib AM,Mensah-Osman E,Aboukameel A,Mohammad R

更新日期：2003-04-01 00:00:00

abstract：:Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant c...

journal_title：Seminars in oncology

authors： Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

更新日期：1988-02-01 00:00:00

abstract：:During the past decade, local control of primary sarcomas of the extremities by radiation and conservative surgery has supplanted more radical compartmental resections or amputations. Reviews of others and our published data show that the probability of achieving local control is highly dependent on achieving negative...

journal_title：Seminars in oncology

authors： Spiro IJ,Gebhardt MC,Jennings LC,Mankin HJ,Harmon DC,Suit HD

更新日期：1997-10-01 00:00:00

abstract：:Hepatic metastases are a major cause of mortality in patients with colorectal carcinoma. The rationale for regional therapy is presented. The randomized studies are reviewed and they demonstrated a significantly higher response rate with hepatic arterial therapy versus systemic therapy. Survival information is difficu...

journal_title：Seminars in oncology

authors： Kemeny N

更新日期：1992-04-01 00:00:00

abstract：:Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

journal_title：Seminars in oncology

authors： Saad F,Eastham J

更新日期：2010-06-01 00:00:00

abstract：:The patient with metastatic adeno- or undifferentiated carcinoma who presents with a cryptic primary is subjected to an extensive diagnostic search. These efforts apparently stem from the following assumptions: 1). The ultimately proven primary sites in such patients will occur with the same frequency as the most comm...

journal_title：Seminars in oncology

authors： Nystrom JS,Weiner JM,Heffelfinger-Juttner J,Irwin LE,Bateman JR,Wolf RM

更新日期：1977-03-01 00:00:00

abstract：:Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO ad...

journal_title：Seminars in oncology

authors： Tropé C,Kaern J

更新日期：1998-06-01 00:00:00

abstract：:Developments in the treatment of extensive small cell lung cancer have proven effective in palliative management but have not yielded improvements in the cure rate for this disease. Strategies involving dose escalation of chemotherapy, including de novo and late intensification dose escalation and dose escalation with...

journal_title：Seminars in oncology

authors： Comis RL

更新日期：1992-12-01 00:00:00

abstract：:Pain is a common, feared, but treatable component of malignancy. The ability, however, to successfully relieve the difficult symptoms of progressive disease, including pain, require an understanding of tumor behavior, complications, and cancer therapy. Despite the treatability of cancer pain and multiple clinical opti...

journal_title：Seminars in oncology

authors： Brescia FJ

更新日期：1993-04-01 00:00:00

abstract：:Thus far the development of adjuvant therapies in melanoma has suffered greatly from the lack of effective drugs in stage IV melanoma. Chemotherapy, cytokines, vaccines, and combinations of drugs have been used with minimal success. This has led to adjuvant therapies that are not used uniformly or widely because of th...

journal_title：Seminars in oncology

authors： Eggermont AM,Testori A,Maio M,Robert C

更新日期：2010-10-01 00:00:00

abstract：:The purpose of this review is to demonstrate a successful use of preclinical models of bladder cancer to confirm the therapeutic potential of new promising drug candidates. The bladder has long been thought to be an ideal target for investigating therapies. When developing a new antineoplastic pharmaceutical agent, th...

journal_title：Seminars in oncology

authors： Amit D,Gofrit ON,Matouk I,Birman T,Hochberg A

更新日期：2012-10-01 00:00:00

abstract：:Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic mali...

journal_title：Seminars in oncology

authors： Simone CB 2nd,Cengel KA

更新日期：2014-12-01 00:00:00

abstract：:The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for pre...

journal_title：Seminars in oncology

authors： Rosenthal DI,Sinard RJ,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Griener J,Frenkel EP,Carbone DP

更新日期：1997-12-01 00:00:00

abstract：:At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

journal_title：Seminars in oncology

authors： Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

更新日期：1992-02-01 00:00:00

abstract：:Spirituality can exert a tremendous impact on ones health and promote recovery from trauma and illness, including cancer. Throughout the history of mankind, spirituality and religion have played a major role in healing a variety of physical and mental illnesses. Cancer is one of the most devastating illnesses, as it a...

journal_title：Seminars in oncology

authors： Torosian MH,Biddle VR

更新日期：2005-04-01 00:00:00

abstract：:Angiogenesis is required for multistage carcinogenesis. The inducible enzyme cyclooxygenase-2 (COX-2) is an important mediator of angiogenesis and tumor growth. COX-2 expression occurs in a wide range of preneoplastic and malignant conditions; and the enzyme has been localized to the neoplastic cells, endothelial cell...

journal_title：Seminars in oncology

authors： Gately S,Li WW

更新日期：2004-04-01 00:00:00